Key result
Quantitative results for subclinical leaflet thrombosis after transcatheter aortic valve replacement were not reported in the truncated abstract.
Why the study?
TAVR can be associated with thromboembolic complications and leaflet thrombosis, but the optimal antithrombotic regimen and the clinical significance of leaflet thrombosis remain debated.
Meta-Analysis
Absence of quantitative data precludes changes to post-TAVR antithrombotic strategies; leaves open the clinical impact of subclinical leaflet thrombosis.
Online publish-ahead-of-print 1 June 2020 Transcatheter aortic valve replacement (TAVR) is the treatment of choice in patients with severe symptomatic aortic stenosis at prohibitive surgical risk, and an alternative to surgical valve replacement (SAVR) in patients at high or intermediate risk.1 Non-inferiority vs. SAVR has been recently reported even in low-risk population.2 Transcatheter aortic valve replacement may be associated with thromboembolic complications both in the peri-procedural setting and at follow-up,3 however, the optimal antithrombotic therapy after the procedure is still a matter of debate. Recent studies reported the occurrence of leaflet thrombosis in transcatheter aortic bioprothesis3 that can be classified as clinical valve thrombosis,...
No takes yet. Share an insight, caveat, or question.
Casula et al. (2020) conducted a meta-analysis in Severe symptomatic aortic stenosis. Subclinical leaflet thrombosis after transcatheter aortic valve replacement was evaluated. Quantitative results for subclinical leaflet thrombosis after transcatheter aortic valve replacement were not reported in the truncated abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: